Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the causative agent of the pandemic coronavirus disease 2019(COVID-19),which threatens human health and public safety.In the urgent campaign to develop ant...Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the causative agent of the pandemic coronavirus disease 2019(COVID-19),which threatens human health and public safety.In the urgent campaign to develop anti-S ARS-CoV-2 therapies,the initial entry step is one of the most appealing targets.In this review,we summarize the current understanding of SARS-CoV-2 cell entry,and the development of targeted antiviral strategies.Moreover,we speculate upon future directions toward nextgeneration of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era.展开更多
基金supported by the Drug Innovation Major Project(No.2018ZX09711001,China)Shandong Provincial Natural Science Foundation,China(No.ZR2020MH383)Qingdao Social Benefiting Technology Program,China(No.21-1-4-rkjk15-nsh)。
文摘Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the causative agent of the pandemic coronavirus disease 2019(COVID-19),which threatens human health and public safety.In the urgent campaign to develop anti-S ARS-CoV-2 therapies,the initial entry step is one of the most appealing targets.In this review,we summarize the current understanding of SARS-CoV-2 cell entry,and the development of targeted antiviral strategies.Moreover,we speculate upon future directions toward nextgeneration of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era.
